Clarified Precision Medicine
Lisa Alderson is a prominent leader in the fields of precision medicine and genomics. Currently serving as the Chief Executive Officer of Adela, Inc. since March 2022, Lisa has focused on innovative blood tests for cancer detection and monitoring. As a co-founder and board director at Clarified Precision Medicine and Genome Medical, Lisa has emphasized accessibility to precision medicine and genetic insights. Previous roles include Chief Commercial Officer and Chief Strategy Officer at Invitae, where efforts centered on integrating genetic information into mainstream healthcare. With extensive experience in venture capital and advisory positions, including work with Illumina Ventures and various startups, Lisa has a strong foundation in business management and entrepreneurship, backed by an MBA from Harvard Business School and a BA from Colorado State University.
This person is not in any teams
Clarified Precision Medicine
Clarified Precision Medicine is the first scalable molecular tumor board with a combination of AI-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit: www.clarifiedprecisionmedicine.com